News 17.12.2018 Schlieren (Zurich), Switzerland, December 17, 2018 – Kuros Biosciences (SIX: KURN) has completed a transformational year, having realized first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to support the roll-out of MagnetOs, and fund the Phase II clinical trial of fibrinPTH (KUR-113) in spinal...
News 10.12.2018 Schlieren (Zurich), Switzerland, December 10, 2018 – Kuros Biosciences (SIX: KURN) today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for extending MagnetOs Putty indications to use as a stand-alone bone graft in extremities and pelvis. This is in addition to the existing...
News 06.12.2018 Zurich-Schlieren, Switzerland, and New York, December 6, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together...
News 06.12.2018 Schlieren (Zurich), Switzerland, December 6, 2018 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study concluded that MagnetOs is a suitable alternative to autograft...
External events
Event date: 28.01.2019
One-day training-workshop “Basics of Regulatory Affairs in Medtech”
January 28th 2019 at ETH Zurich-Zentrum
This workshops provides you with the basics of regulatory affairs in Medtech with the focus on MDR and IVDR. Get an overview of the regulatory landscape, hear about the basic concepts and principles and get insights into...